IA
BCLI

IFP Advisors’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

IFP Advisors’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,777
Closed -$139K – 3447
2022
Q4 		$139K Sell
1,777
-146
-8% -$5.46K ﹤0.01% 1556
2022
Q3 		$151K Buy
1,923
+600
+45% +$30.1K ﹤0.01% 1584
2022
Q2 		$104K Hold
1,323
– – ﹤0.01% 1661
2022
Q1 		$104K Buy
+1,323
New +$64.9K ﹤0.01% 1661

Other funds holding BCLI

ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return
AHB
Abner Herrman & Brock Jersey City, New Jersey $1.05B AUM 42.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

IFP Advisors's BCLI Position: Q1 2023 in Review

IFP Advisors sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q1 2023, closing a stake of 1,777 shares — an estimated $139K sold.

IFP Advisors first reported a position in BCLI in Q1 2022 and held it in 4 quarters. The position peaked at $151K in Q3 2022. 48 funds tracked by Wall St. Rank hold BCLI as of Q1 2023.

  • IFP Advisors reported no remaining BRAINSTORM CELL THERAPUTC position as of Q1 2023 after selling out during the quarter.
  • IFP Advisors sold 1,777 BRAINSTORM CELL THERAPUTC shares in Q1 2023, an estimated $139K.
  • IFP Advisors first reported a position in BRAINSTORM CELL THERAPUTC in Q1 2022 and held it in 4 quarters.
  • IFP Advisors's BRAINSTORM CELL THERAPUTC position peaked at $151K in Q3 2022.
  • 48 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q1 2023.

Based on IFP Advisors's 13F filing for Q1 2023, filed 18 Apr 2023.